

IMPACT FACTOR 3.4

Indexed in: PubMed



an Open Access Journal by MDPI

Personalized Cardiovascular Medicine

Guest Editor:

Dr. Agata Bielecka-Dąbrowa

1. Department of Cardiology and Congenital Diseases of Adults, Polish Mother's Memorial Hospital Research Institute (PMMHRI), 93-338 Lodz, Poland 2. Department of Preventive Cardiology and Lipidology, Medical University of Lodz, Lodz, Poland

Deadline for manuscript submissions:

closed (15 January 2022)

Message from the Guest Editor

Dear Colleagues,

Personalized medicine is the practice of tailoring medical treatment to the individual characteristics of each patient. Personalized medicine includes identifying patients most likely to benefit and those most likely to experience adverse reactions in response to a drug, and also tailoring therapy based on pharmacokinetics or pharmacodynamic response. This Special Issue of the *Journal of Personalized* Medicine will highlight the current state of the art and showcase some of the latest findings in the field of personalized cardiovascular medicine. This involves the evaluation of biomarkers, expanded advanced risk factor analysis, micronutrient testing, risk scoring systems, cardiovascular genetics, gene expression testing, and noninvasive and invasive cardiovascular testing, as well as research and debate about the effectiveness of personalized medicine as a more suitable tool for the prevention and treatment of cardiovascular diseases than the traditional one-size-fits-all recommendations

Dr. Agata Bielecka-Dabrowa Guest Editor







IMPACT FACTOR 3.4





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

 Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
Division of Hematologic Malignancies and Cellular Therapy, Duke University,

Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous*))

Contact Us